Literature DB >> 28276727

Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.

Manar M Ismail1,2, Heba K Morsi1,3, Nahla A B Abdulateef2,4, Maissa K Noaman5, Ghada A Abou El-Ella1,6.   

Abstract

Hepatocellular carcinoma (HCC) represents a challenging malignancy of worldwide importance. It is the third most common cause of cancer-related death globally as most patients present with unresectable disease. Alpha-fetoprotein (AFP) is the widely and solely used biomarker for HCC diagnosis; yet, its usefulness is hampered by low sensitivity and specificity. We aimed to identify more sensitive biomarkers for HCC diagnosis and a surveillance algorithm that may facilitate early detection of HCC. A total of 305 Egyptian and Saudi participants grouped as healthy controls, cancer controls, benign hepatic lesions, chronic viral hepatitis and HCC were included. Serum AFP, prothrombin induced by vitamin K absence-II (PIVKA-II), macrophage migration inhibitory factor (MIF) and Golgi protein-73 (GP-73) levels were quantitated by enzyme immunoassay. Significantly higher levels of GP-73 and PIVKA-II were detected in the HCC group than in all other groups, while MIF showed a highly significant increase in HCC from all groups except the cancer control group. The HCC group showed no significant difference between the studied biomarkers and the type of chronic viral hepatitis. On the basis of multiple ROC curve analyses, GP-73 and PIVKA-II showed the highest sensitivity and specificity for surveillance and diagnosis. In conclusion, PIVKA-II and GP-73 offer an effective approach for early HCC diagnosis and surveillance of high-risk groups with a higher accuracy than AFP. MIF may serve as a promising screening tumor marker for the detection of gastrointestinal tract (GIT) malignancy.

Entities:  

Keywords:  Biomarkers; ROC curve; chronic hepatitis; hepatocarcinogenesis; screening; sensitivity; specificity

Mesh:

Substances:

Year:  2017        PMID: 28276727     DOI: 10.1080/00365513.2017.1286684

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  7 in total

Review 1.  Biomarker development for hepatocellular carcinoma early detection: current and future perspectives.

Authors:  Shreya Sengupta; Neehar D Parikh
Journal:  Hepat Oncol       Date:  2017-11-17

2.  Hepatitis B virus upregulates GP73 expression by activating the HIF-2α signaling pathway.

Authors:  Sheng-Li Yang; Cui Zeng; Xiefan Fang; Qian-Jin He; Li-Ping Liu; Shi-Yun Bao; Xiaoli Pan; Zhi-Fan Xiong
Journal:  Oncol Lett       Date:  2018-02-05       Impact factor: 2.967

3.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

Review 4.  Recent advances in liver transplantation for cancer: The future of transplant oncology.

Authors:  Phillipe Abreu; Andre Gorgen; Graziano Oldani; Taizo Hibi; Gonzalo Sapisochin
Journal:  JHEP Rep       Date:  2019-07-30

5.  Validation of the hepatocellular carcinoma early detection screening algorithm Doylestown and aMAP in a cohort of Chinese with cirrhosis.

Authors:  Yunsong Qian; Linhong Li; Li Ma; Rengbin Ji; Sheng Ying; Juhong Zhou; Liyun Fu; Gang Yang
Journal:  J Clin Lab Anal       Date:  2022-02-26       Impact factor: 2.352

6.  Biomarkers for the Early Detection of Hepatocellular Carcinoma.

Authors:  Neehar D Parikh; Anand S Mehta; Amit G Singal; Timothy Block; Jorge A Marrero; Anna S Lok
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-01       Impact factor: 4.254

7.  The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma.

Authors:  Famei Qi; Aihua Zhou; Li Yan; Xiumei Yuan; Danni Wang; Ruoyun Chang; Yujun Zhang; Funa Shi; Xiaomei Han; Jinxia Hou; Lianhua Wei; Xu Zhang
Journal:  J Clin Lab Anal       Date:  2019-12-10       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.